PTGX Q2 2025 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+33.1% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$42M-758.0% margin

Net Income

-$35M-627.0% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

-80.4%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$718M

Total Liabilities

$50M

Stockholders' Equity

$668M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+33.1%
Gross Profit	$6M	$4M	+33.1%
Operating Income	-$42M	-$39M	-8.4%
Net Income	-$35M	-$31M	-13.6%